Philadelphia, PA – In a significant development for the treatment of chronic hepatitis B virus (HBV) infection, Virion Therapeutics announced compelling data from its Phase 1b study evaluating VRON-0200. Presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI) in Denver, Colorado, on February 22, 2026, the findings demonstrate that a single dose of VRON-0200 can elicit broad and sustained anti-HBV immunity in a majority of chronically infected patients. This represents a potential step forward in the pursuit of a functional cure for this widespread and often debilitating disease.
Chronic HBV infection affects an estimated 296 million people globally, and despite the availability of preventative vaccines, it remains a major public health concern. Current antiviral treatments rarely achieve a functional cure, often requiring lifelong medication. The challenge lies in the virus’s ability to impair the body’s own immune response, specifically CD8+ T cells, which are crucial for controlling the infection. VRON-0200 aims to address this by reinvigorating these exhausted immune cells, offering a new approach to achieving lasting viral control.
VRON-0200: Reawakening the Immune System
VRON-0200 is a first-in-class immunotherapy designed to modify immune checkpoints, effectively lowering the activation threshold for CD8+ T cells. As explained in the study data presented at CROI 2026, this allows the immune system to more effectively recognize and attack HBV-infected cells. The Phase 1b trial showed that a single intramuscular dose of VRON-0200 was able to “spark” and re-awaken durable HBV-specific immunity in the majority of patients enrolled. Notably, declines in hepatitis B surface antigen (HBsAg) – a key marker of viral activity – were sustained or even deepened through Day 360 following treatment.
Dr. Sue Currie, PhD, of Virion Therapeutics, commented on the significance of the findings, stating that the field is at “a pivotal point in the development of potential functional cures for chronic HBV,” with exciting progress being made across different treatment classes. Yet, she emphasized that many therapies are limited by their inability to restore a patient’s own immune responses. “once treatment is discontinued, viral rebound typically occurs in a large proportion of patients,” Dr. Currie noted. “The field now believes that immune modulators are necessary to mitigate this virological rebound.”
Synergy with Antiviral Agents and Favorable Safety Profile
The study also highlighted the rapid and profound synergy observed when VRON-0200 was combined with antiviral agents designed to lower antigen levels. This combination approach appears to enhance the effectiveness of both therapies, potentially leading to more durable responses. Importantly, VRON-0200 demonstrated a favorable safety and tolerability profile throughout the trial, providing reassurance for its potential clinical application.
Previous research, as detailed in a January 10, 2025 press release, showed that even a single injection of VRON-0200 could induce immune responses and anti-HBV activity in patients with highly impaired HBV immunity prior to treatment. A third cohort of the Phase 1b trial is currently underway, investigating VRON-0200 in combination with several investigational anti-HBV agents.
Looking Ahead
The data presented at CROI 2026 represent a promising step towards developing effective immunotherapies for chronic HBV infection. Further research will be crucial to confirm these findings in larger clinical trials and to optimize combination therapies. The potential of VRON-0200 to restore immune control and achieve a functional cure for millions living with chronic HBV remains a significant area of focus for Virion Therapeutics and the broader scientific community. The company continues to explore the potential of VRON-0200 as a key component of future HBV functional cure regimens.
What are your thoughts on these promising developments in HBV treatment? Share your comments below, and please share this article with your network.
Disclaimer: This article is for informational purposes only and should not be considered medical advice. Please consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
